To the full analysis
Jazz Pharmaceuticals stock: growth
JAZZJazz Pharmaceuticals reported $4.27B in revenue for fiscal 2025, up 4.9% on the prior year, up 12.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
27.1%
per year from 2006 to 2025, per share 17.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 12.5% | 12.4% | 27.1% |
| Revenue per share | 10.5% | 12.5% | 17.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 17.1% | 8.7% | no data |
| Free cash flow per share | 15.0% | 8.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $44.86M | −$59.39M | −$59.03M |
| 2007 | $65.3M | −$138.83M | −$84.24M |
| 2008 | $67.51M | −$184.34M | −$158.97M |
| 2009 | $128.45M | −$6.84M | −$21.93M |
| 2010 | $173.78M | $32.78M | $54.14M |
| 2011 | $272.28M | $124.98M | $145.82M |
| 2012 | $585.98M | $288.59M | $227.28M |
| 2013 | $872.42M | $216.31M | $272.34M |
| 2014 | $1.17B | $58.39M | $166.79M |
| 2015 | $1.32B | $329.54M | $495.99M |
| 2016 | $1.49B | $396.83M | $408.95M |
| 2017 | $1.62B | $487.85M | $579.14M |
| 2018 | $1.89B | $447.1M | $667.43M |
| 2019 | $2.16B | $523.37M | $594.07M |
| 2020 | $2.36B | $238.62M | $520.39M |
| 2021 | $3.09B | −$328.95M | $732.98M |
| 2022 | $3.66B | −$224.06M | $773.78M |
| 2023 | $3.83B | $414.83M | $1.07B |
| 2024 | $4.07B | $560.12M | $1.35B |
| 2025 | $4.27B | −$356.15M | $1.15B |
Revenue by segment
How Jazz Pharmaceuticals plc makes its money and how that has shifted. Names are as the company reports them.
- Xywav39%
- Epidiolex/Epidyolex25%
- Rylaze/Enrylaze9%
- Zepzelca7%
- High Sodium AG Oxybate Product Royalty Revenue5%
- Defitelio/Defibrotide5%
- Other10%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Xywav | $1.47B | $1.66B | 38.8% |
| Epidiolex/Epidyolex | $972.42M | $1.06B | 24.8% |
| Rylaze/Enrylaze | $410.85M | $402.92M | 9.4% |
| Zepzelca | $320.32M | $307.31M | 7.2% |
| High Sodium AG Oxybate Product Royalty Revenue | $217.58M | $211.73M | 5% |
| Defitelio/Defibrotide | $216.57M | $199.39M | 4.7% |
| Other | $458.02M | $430.06M | 10.1% |
| Total revenue | $4.07B | $4.27B | 100% |
Revenue by region
Where Jazz Pharmaceuticals plc generates its revenue.
- United States90%
- Europe8%
- Other2%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $3.66B | $3.83B | 89.8% |
| Europe | $312.71M | $341.12M | 8% |
| Other | $96.14M | $94.87M | 2.2% |
| Total revenue | $4.07B | $4.27B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.